Macleods Pharmaceuticals Ltd

Mumbai, India

Macleods Pharmaceuticals Ltd

Mumbai, India
SEARCH FILTERS
Time filter
Source Type

PubMed | The Global Alliance for TB Drug Development, Macleods Pharmaceuticals Ltd and University of Cape Town
Type: | Journal: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease | Year: 2015

There is a growing number of children worldwide accessing second-line anti-tuberculosis drugs for multidrug-resistant tuberculosis (TB); however, there are very few child-friendly formulations. For paediatric use, dispersible tablets offer distinct advantages over liquid formulations and other approaches. This is particularly relevant for TB, where stability, long shelf-life and reduced manufacturing, transport and storage costs are all critical to ensuring that drugs are accessible and affordable. In addition, fixed-dose combinations that reduce the pill burden and provide adequate taste masking may promote long-term adherence to anti-tuberculosis treatment and prevention regimens likely to last many months in children. Partial adherence may result in treatment failure and the further selection and spread of resistant mycobacteria. Unfortunately, no second-line TB paediatric drugs exist in dispersible formulations. We discuss here the main obstacles to developing such tablets and present strategies for overcoming them. We also advocate for timely anticipation of paediatric use when new TB drugs are being developed, and for the development of child-friendly anti-tuberculosis formulations in general.


Basu B.,Atmiya Institute of Pharmacy | Aviya K.R.,Atmiya Institute of Pharmacy | Bhattacharya A.,Macleods Pharmaceuticals Ltd.
Journal of Pharmaceutical Investigation | Year: 2014

Prednisolone is a glucocorticoid with the general properties of the corticosteroids. It is used as anti-inflammatory or immunosuppressive agent in asthmatic condition mostly in pediatric and geriatric population. So the present investigation was conducted with an aim of to formulate a taste masked patient friendly dosage form i.e. mouth dissolving tablets of prednisolone. In this study, taste masking of drug was critical parameter for this study. Masking of bitter taste of prednisolone was carried out using techniques like preparation of solid dispersion with PEG 6000, complex formation with Indion-204 resin and β-cyclodextrin. Among them complex prepared from β-cyclodextrin in weight ratio 1:4 was optimized basis on taste panel evaluation and drug release from complex. A successful taste masking of complex was confirmed by time intensity method and also by taking drug release in simulated gastric fluid and in simulated salivary fluid. The values of pre-compression parameters evaluated, were within prescribed limits and indicated good free flowing properties. Tablets optimization was carried out through 32 full factorial designs, concentration of superdisintegrants like croscarmellose sodium and sodium starch glycolate as independent variable. Whereas wetting time, disintegrating time and cumulative percentage of drug release as dependent variable. The data obtained of post-compression parameters such as weight variation, hardness, friability, wetting time, water absorption ratio, content uniformity, disintegration time and dissolution was found within specified limit. Prepared check point batch having disintegrating time 16.12 s and drug release 98.34 after 30 min was selected as optimized formula. This formula was compared with marketed formulation and was found better disintegration and drug release property. Optimized formulation was subjected for accelerated stability study as per ICH guideline. © 2013 The Korean Society of Pharmaceutical Sciences and Technology.


Saravanan M.,Dr. Reddys Laboratories Ltd. | Saravanan M.,Andhra University | Satyanarayana B.,Macleods Pharmaceuticals Ltd. | Reddy P.P.,Macleods Pharmaceuticals Ltd.
Synthetic Communications | Year: 2013

A new and practical synthesis of montelukast sodium, an antiasthmatic drug, is described. The key steps are the synthesis of nitrile derivative 4 by chiral reduction of keto ester 9 using (-)-DIP-Cl, synthesis of vinylquinoline framework 16 by Wittig reaction, and Heck coupling of nitrile 4 with vinylquinoline 16. The method is operationally simple and suitable for the industrial production of the drug substance. Supplemental materials are available for this article. Go to the publisher's online edition of Synthetic Communications® to view the free supplemental file. © 2013 Taylor and Francis Group, LLC.


PubMed | Macleods Pharmaceuticals Ltd and Seth G S Medical College & KEM Hospital
Type: Journal Article | Journal: Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine | Year: 2014

Critically ill patients requiring mechanical ventilation frequently need sedatives and analgesics to facilitate their care. Dexmedetomidine, a short-acting alpha-2-agonist, possesses anxiolytic, anesthetic, hypnotic, and analgesic properties.The objective of this study was to evaluate the efficacy and safety of dexmedetomidine in comparison to propofol in the management of sedation for post-operative intensive care unit (ICU) patients, as a sedative agent.Teaching hospital, A phase III, prospective, open, randomized and comparative.Thirty patients who were ambulatory and who required the post-operative mechanical ventilation or post-operative sedation were enrolled, in which 15 patients received Dexmedetomidine and remaining 15 patients received propofol. All these patients were treated for the period of 8 to 24 h.Data were analyzed using Students t-test and Chi-square test. The value of P < 0.05 was considered as statistically significant.Demographic data were comparable. Pulse rate, respiratory rate and blood pressure were comparable. Depth of sedation and extubation time were similar. To maintain analgesia throughout the study period, patients receiving propofol infusions required significantly more analgesics than patients receiving Dexmedetomidine.Dexmedetomidine appears to be a safe and acceptable ICU sedative agent when both the clinicians and patients perspectives are considered.


Aalla S.,Dr. Reddys Laboratories Ltd | Gilla G.,Dr. Reddys Laboratories Ltd | Bojja Y.,Dr. Reddys Laboratories Ltd | Anumula R.R.,Dr. Reddys Laboratories Ltd | And 2 more authors.
Organic Process Research and Development | Year: 2012

An efficient, telescopic, and scalable process for an antihypertensive drug substance, valsartan with an overall yield of 58%, and ∼99.9% purity is described. A simple, and safe process is developed for the recovery of tributyltin chloride from the tributyltin hydroxide, byproduct formed in the tetrazole ring construction, and reused in the synthesis of valsartan. © 2012 American Chemical Society.


Aalla S.,Dr. Reddys Laboratories Ltd. | Gilla G.,Dr. Reddys Laboratories Ltd. | Metil D.S.,Dr. Reddys Laboratories Ltd. | Anumula R.R.,Dr. Reddys Laboratories Ltd. | And 2 more authors.
Organic Process Research and Development | Year: 2012

An improved process for the synthesis of prasugrel hydrochloride with an overall yield of 58%, 99.9% purity, and meeting all other quality requirements is described. © 2012 American Chemical Society.


Aalla S.,Dr. Reddys Laboratories Ltd. | Gilla G.,Dr. Reddys Laboratories Ltd. | Anumula R.R.,Dr. Reddys Laboratories Ltd. | Kurella S.,Dr. Reddys Laboratories Ltd. | And 2 more authors.
Organic Process Research and Development | Year: 2012

An improved process has been developed for the active pharmaceutical ingredient, ranolazine with 99.9% purity and 47% overall yield (including three chemical reactions and one recrystallization). Formation and control of all the possible impurities is described. All the solvents used in the process were recovered and reused. The unreacted piperazine is recovered as piperazine monophosphate monohydrate salt. © 2012 American Chemical Society.


Pratap Reddy P.,Macleods Pharmaceuticals Ltd | Mukkanti K.,Jawaharlal Nehru Technological University | Purandhar K.,Matrix
Rasayan Journal of Chemistry | Year: 2010

An efficient method has been developed for the synthesis of 1,2,4,5-tetrasubtituted imidazoles by four-component condensation of benzil or benzoin, aldehydes, amines, and ammonium acetate under microwave irradiation or classical heating conditions using Aluminium Phosphate (AlPO4: a heterogeneous catalyst). The catalyst exhibited remarkable reusable activity.


Shah P.N.,KEM Hospital | Dongre V.,KEM Hospital | Patil V.,KEM Hospital | Pandya S.,KEM Hospital | And 2 more authors.
Indian Journal of Critical Care Medicine | Year: 2014

Context: Critically ill patients requiring mechanical ventilation frequently need sedatives and analgesics to facilitate their care. Dexmedetomidine, a short-acting alpha-2-agonist, possesses anxiolytic, anesthetic, hypnotic, and analgesic properties. Aims: The objective of this study was to evaluate the efficacy and safety of dexmedetomidine in comparison to propofol in the management of sedation for post-operative intensive care unit (ICU) patients, as a sedative agent. Settings and Design: Teaching hospital, A phase III, prospective, open, randomized and comparative. Materials and Methods: Thirty patients who were ambulatory and who required the post-operative mechanical ventilation or post-operative sedation were enrolled, in which 15 patients received Dexmedetomidine and remaining 15 patients received propofol. All these patients were treated for the period of 8 to 24 h. Statistical Analysis Used: Data were analyzed using Student's t-test and Chi-square test. The value of P < 0.05 was considered as statistically significant. Results: Demographic data were comparable. Pulse rate, respiratory rate and blood pressure were comparable. Depth of sedation and extubation time were similar. To maintain analgesia throughout the study period, patients receiving propofol infusions required significantly more analgesics than patients receiving Dexmedetomidine. Conclusions: Dexmedetomidine appears to be a safe and acceptable ICU sedative agent when both the clinician's and patient's perspectives are considered.


Trademark
Macleods Pharmaceuticals Ltd. | Date: 2012-05-10

pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, blood, psychiatric and immune system related diseases and disorders; antibiotic preparations; pharmaceutical anti-allergic preparations; pharmaceutical preparations for the treatment of pain; all of the foregoing goods for human use.

Loading Macleods Pharmaceuticals Ltd collaborators
Loading Macleods Pharmaceuticals Ltd collaborators